Article

Risk of hepatitis B virus reactivation in B-cell malignancies treated with BTK inhibitors

2025-06-09

Abstract excerpt

<title>Abstract</title> <p>Background In the era of immunotherapy, Bruton’s tyrosine kinase (BTK) inhibitors are increasingly used to treat B-cell malignancies. We aimed to investigate the reactivation of hepatitis B virus (HBV) in patients receiving BTK inhibitors. Methods Medical records were reviewed to identify patients with B cell malignancies treated with BTK inhibitors at Taizhou Hospital of Zhejiang Pro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: da3e52e3-58fd-5591-b3fd-9427d071bdc4
DOI: 10.21203/rs.3.rs-6756073/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Risk of hepatitis B virus reactivation in B-cell malignancies treated with BTK inhibitorsDOI 10.21203/rs.3.rs-6756073/v1Read

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.Semantic proximity Read

Zanubrutinib: Coming of Age for BTK Inhibitors in the Treatment of Chronic Lymphocytic Leukemia?Semantic proximity Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read

Antiviral Therapy Inhibited HBV-reactivation and Improved Long-term Outcomes in Patients Who Underwent Radiofrequency Ablation for HBV-related Hepatocellular CarcinomaSemantic proximity Read

Rocbrutinib in Covalent BTK Inhibitor Exposed Relapsed or Refractory Mantle Cell Lymphoma: a Phase 2, Open-label, Multicenter, Single-arm StudySemantic proximity Read

Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID eraSemantic proximity Read

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read